ZVRA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ZV

Mkt Cap

$589.7M

Volume

488.66K

Next Earnings

November 4th

Loading chart

ZV

ZVRAZevra Therapeutics, Inc. Common Stock

ZVRA

Pay with—

Available Balance0.00

ZV

Mkt Cap

$609.9M

Volume

488.66K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumZevra Therapeutics announced the presentation of long-term real-world data on MIPLYFFA (arimoclomol) for treating Niemann-Pick disease type C at the 2026 SSIEM Annual Symposium. Data from U.S. and German early access programs demonstrate sustained disease stabilization over up to 8 years with a consistent safety profile across diverse patient populations, including adults and children. The pivotal trial showed a 65% reduction in disease progression compared to placebo.GlobeNewswire Inc. · Aug 25, 2026

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionZevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C. The company plans to request a re-examination of the decision and continues supporting patient access through its Expanded Access Program.GlobeNewswire Inc. · Jul 24, 2026

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business AchievementsXOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.GlobeNewswire Inc. · Mar 18, 2026

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Zevra Therapeutics announced granting options to purchase 38,000 shares of common stock to two new employees under its 2023 Employment Inducement Award Plan, with options vesting over four years.GlobeNewswire Inc. · Oct 6, 2025

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionZevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, strengthening its balance sheet and supporting its strategic priorities.Benzinga · Feb 27, 2025

Zevra Therapeutics Announces Organizational ChangesZevra Therapeutics is consolidating its development and scientific functions under the Chief Medical Officer, resulting in the departure of the Chief Development Officer and Chief Scientific Officer. The company is also discontinuing its in-house drug discovery activities and closing its laboratory facilities to focus on late-stage clinical development and commercial opportunities.GlobeNewswire Inc. · Dec 6, 2024

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CZevra Therapeutics announced the commercial availability of MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C. The company's comprehensive patient support program, AmplifyAssist, is in place to address access barriers.GlobeNewswire Inc. · Nov 21, 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingZevra Therapeutics will present data at the 53rd Child Neurology Society Annual Meeting, demonstrating the relevance of the swallow domain in the Niemann-Pick disease Type C Clinical Severity Scale (NPCCSS). The study indicates that the NPCCSS swallow score reflects the patient's level of dysfunction, and a change in score reflects actual improvement or worsening in a patient's swallowing function.GlobeNewswire Inc. · Nov 11, 2024

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type CThe FDA Genetic Metabolic Diseases Advisory Committee voted favorably that the data support arimoclomol as an effective treatment for Niemann-Pick disease type C, a rare and progressive neurodegenerative disorder. The committee's recommendation will be considered by the FDA as it completes its review of the arimoclomol new drug application.GlobeNewswire Inc. · Aug 2, 2024

Zevra Therapeutics Expands Executive Leadership TeamRahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance OfficerGlobeNewswire Inc. · Jun 25, 2024

to start trading

ZV

ZVRAZevra Therapeutics, Inc. Common Stock

ZVRA

Pay with—

Available Balance0.00

Your PositionYou don't own any ZVRA yet.

Related Tickers

Earnings